Monday, February 6, 2023
Bringing the Latest in News Straight to Your Screen

U.S. Inks $5.3 Billion Deal For Pfizer’s Antiviral Covid Pill — Growing Its Stockpile Of New Coronavirus Treatments

By News Creatives Authors , in Business , at November 18, 2021


The U.S. government has signed a deal to purchase 10 million courses of Pfizer’s antiviral Covid-19 pill, the company announced Thursday, the latest in a string of purchases as officials secure limited supplies of new coronavirus treatments. 

Key Facts

The U.S. will spend around $5.3 billion on Pfizer’s drug, Paxlovid, the company said, conditional on it being approved for use by the Food and Drug Administration (FDA).

Pfizer said it will start delivering the courses later this year and will complete the order in 2022. 

The deal adds to a growing U.S. stockpile of new therapies that experts feel could mark a turning point in the pandemic. 

The U.S. signed two deals with Merck and Ridgeback Biotherapeutics to buy 3.1 million courses of another antiviral pill, molnupiravir, which regulators are expected to review at the end of November. 

The government has also agreed to buy 700,000 doses of AstraZeneca’s injectable antibody cocktail, which trials indicate can reduce the risk of death or severe Covid-19 and also protect against symptomatic infection. 

Key Background

Oral antivirals could change the face of the Covid-19 pandemic, turning the virus into something that is easily treatable outside of hospital settings. Pfizer said Paxlovid—a combination of a Covid-19 antiviral agent and ritonavir, an antiviral used to treat HIV—can slash the risk of hospitalization or death from Covid-19 by 89% if taken shortly after the onset of symptoms, while Merck said molnupiravir can cut the risk in half. While neither have been approved in the U.S., the U.K. greenlit molnupiravir on an emergency basis in early November, the first country in the world to do so. Supply is likely to be a key constraining factor, and both companies have signed deals to share the poll with low income nations and ramp up production. 

Further Reading

U.S. Inks $1 Billion Deal For Extra Doses Of Merck’s Antiviral Covid Pill (Forbes)

Pfizer Says Its Covid Pill Reduced Risk Of Hospitalization And Death By 89% In Clinical Study (Forbes)

Pfizer Signs Deal To Share Its Covid Antiviral Pill With Low Income Nations (Forbes)

New antiviral drugs mark a big turning point in the covid-19 pandemic (Economist)

Full coverage and live updates on the Coronavirus


Leave a Reply

Your email address will not be published. Required fields are marked *